{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:57:48Z","timestamp":1762001868846},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11892-018-1117-y","type":"journal-article","created":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T20:51:28Z","timestamp":1540759888000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes"],"prefix":"10.1007","volume":"18","author":[{"given":"Ilaria","family":"Cavallari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Delli Veneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Maddaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosetta","family":"Melfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germano","family":"Di Sciascio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"1117_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 8th Edn, 2017. \n                      http:\/\/diabetesatlas.org\/resources\/2017-atlas.html\n                      \n                    . Accessed September 17, 2018."},{"key":"1117_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/0002-8703(85)90224-8","volume":"110","author":"WB Kannel","year":"1985","unstructured":"Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110:1100\u20137.","journal-title":"Am Heart J"},{"key":"1117_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.298.7.765","volume":"298","author":"SM Donahoe","year":"2007","unstructured":"Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765\u201375.","journal-title":"JAMA"},{"key":"1117_CR4","doi-asserted-by":"crossref","unstructured":"Hermans MP, Valensi P, Ahn SA, Rousseau MF. [HDL-C\/apoA-I]: a multivessel cardiometabolic risk marker in women with T2DM. Diabetes Metab Res Rev. 2018;34.","DOI":"10.1002\/dmrr.2950"},{"key":"1117_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12020-013-0128-3","volume":"46","author":"E Maddaloni","year":"2014","unstructured":"Maddaloni E, Pozzilli P. SMART diabetes: the way to go (safe and multifactorial approach to reduce the risk for therapy in diabetes). Endocrine. 2014;46:3\u20135.","journal-title":"Endocrine"},{"key":"1117_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","volume":"316","author":"RC Turner","year":"1998","unstructured":"Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823\u20138.","journal-title":"BMJ"},{"key":"1117_CR7","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.2337\/dc18-S009","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S86\u2013S104.","journal-title":"Diabetes Care"},{"key":"1117_CR8","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff","year":"2014","unstructured":"Goff DC, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49\u201373.","journal-title":"Circulation"},{"key":"1117_CR9","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999\u20133058.","journal-title":"Eur Heart J"},{"key":"1117_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2008","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (London, England). 2008;371:117\u201325.","journal-title":"Lancet (London, England)"},{"key":"1117_CR11","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"1117_CR12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"\u2022 Lloyd-Jones DM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-Statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force. J Am Coll Cardiol. 2017;70:1785\u2013822 This document provides a focused update to help guide clinicians on decision making regarding the use of non-statin therapies in patients with clinical atherosclerotic cardiovascular disease with or without comorbidities.","journal-title":"J Am Coll Cardiol"},{"key":"1117_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1\u201387.","journal-title":"Endocr Pract"},{"key":"1117_CR14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2337\/diacare.28.5.1029","volume":"28","author":"AG Kennedy","year":"2005","unstructured":"Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 2005;28:1029\u201334.","journal-title":"Diabetes Care"},{"key":"1117_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"\u2022 Silverman MG, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289\u201397. This study demonstrated that the use of statin and nonstatin therapies that act via upregulation of LDL receptor expression to reduce LDL-C are associated with similar risk reductions of major major vascular events per change in LDL-cholesterol.","journal-title":"JAMA"},{"key":"1117_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","volume":"56","author":"AM Dattilo","year":"1992","unstructured":"Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320\u20138.","journal-title":"Am J Clin Nutr"},{"key":"1117_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.2014.10706","volume":"312","author":"N Puzziferri","year":"2014","unstructured":"Puzziferri N, Roshek TB III, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312:934\u201342.","journal-title":"JAMA"},{"key":"1117_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ahj.2012.04.014","volume":"164","author":"KM Huffman","year":"2012","unstructured":"Huffman KM, Hawk VH, Henes ST, Ocampo CI, Orenduff MC, Slentz CA, et al. Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I. Am Heart J. 2012;164:117\u201324.","journal-title":"Am Heart J"},{"key":"1117_CR19","first-page":"378","volume":"e34","author":"R Estruch","year":"2018","unstructured":"Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;e34:378.","journal-title":"N Engl J Med"},{"key":"1117_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, W Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet (London, England). 2004;364:685\u201396.","journal-title":"Lancet (London, England)"},{"key":"1117_CR21","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)12475-0","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, et al. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (London, England). 2003;361:2005\u201316.","journal-title":"Lancet (London, England)"},{"key":"1117_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2165\/00003495-200464002-00005","volume":"64","author":"PS Sever","year":"2004","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial - lipid lowering arm (ASCOT-LLA): a multicentre randomi. Drugs. 2004;64:43\u201360.","journal-title":"Drugs"},{"key":"1117_CR23","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/dc05-2415","volume":"29","author":"RH Knopp","year":"2006","unstructured":"Knopp RH, D\u2019Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478\u201385.","journal-title":"Diabetes Care"},{"key":"1117_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111247","volume":"9","author":"FM Vries de","year":"2014","unstructured":"de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS One. 2014;9:e111247.","journal-title":"PLoS One"},{"key":"1117_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (London, England). 2010;375:735\u201342.","journal-title":"Lancet (London, England)"},{"key":"1117_CR26","doi-asserted-by":"crossref","unstructured":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351\u201364.","DOI":"10.1001\/jama.251.3.351"},{"key":"1117_CR27","doi-asserted-by":"crossref","unstructured":"Pre-entry characteristics of participants in the Lipid Research Clinics\u2019 Coronary Primary Prevention Trial. J Chronic Dis. 1983;36:467\u201379.","DOI":"10.1016\/0021-9681(83)90138-8"},{"key":"1117_CR28","doi-asserted-by":"crossref","unstructured":"The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch Intern Med. 1992;152:1399\u2013410.","DOI":"10.1001\/archinte.152.7.1399"},{"key":"1117_CR29","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"AIM-HIGH Investigators","year":"2011","unstructured":"AIM-HIGH Investigators, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"1117_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203\u201312.","journal-title":"N Engl J Med"},{"key":"1117_CR31","doi-asserted-by":"publisher","first-page":"1943 LP","DOI":"10.1161\/01.CIR.0000034044.95911.DC","volume":"106","author":"T Sudhop","year":"2002","unstructured":"Sudhop T, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943 LP\u20131948.","journal-title":"Circulation"},{"key":"1117_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1567-5688(01)80026-X","volume":"2","author":"T Kosoglou","year":"2001","unstructured":"Kosoglou T, Guillaume M, Sun S, Pember LJC, Reyderman L, Statkevich P, et al. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. Atherosclerosis. 2001;2:38.","journal-title":"Atherosclerosis"},{"key":"1117_CR33","first-page":"415","volume":"8","author":"BAP Phan","year":"2012","unstructured":"Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415\u201327.","journal-title":"Vasc Health Risk Manag"},{"key":"1117_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.diabres.2012.12.026","volume":"100","author":"T Tsunoda","year":"2013","unstructured":"Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013;100:46\u201352.","journal-title":"Diabetes Res Clin Pract"},{"key":"1117_CR35","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","volume":"93","author":"CM Ballantyne","year":"2004","unstructured":"Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487\u201394.","journal-title":"Am J Cardiol"},{"key":"1117_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jacl.2007.12.004","volume":"2","author":"JR Guyton","year":"2008","unstructured":"Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, et al. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe\/simvastatin compared with atorvastatin in type 2 diabetes. J Clin Lipidol. 2008;2:19\u201324.","journal-title":"J Clin Lipidol"},{"key":"1117_CR37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jjcc.2011.09.001","volume":"59","author":"Y Uemura","year":"2012","unstructured":"Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, et al. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012;59:50\u20136.","journal-title":"J Cardiol"},{"key":"1117_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: The multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495\u2013507. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2015.05.065\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"key":"1117_CR39","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"issue":"15","key":"1117_CR40","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal\u00e1n R, \u0160pinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with vs. without diabetes: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571\u201382. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030950\n                      \n                    .","journal-title":"Circulation"},{"key":"1117_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251\u201361.","journal-title":"Atherosclerosis"},{"key":"1117_CR42","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088\u201393.","journal-title":"Circulation"},{"key":"1117_CR43","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"T Field","year":"2005","unstructured":"Field T. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet"},{"key":"1117_CR44","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2337\/diacare.15.7.820","volume":"15","author":"P Koskinen","year":"1992","unstructured":"Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820\u20135. \n                      https:\/\/doi.org\/10.2337\/diacare.15.7.820\n                      \n                    .","journal-title":"Diabetes Care"},{"key":"1117_CR45","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0002-9149(96)00369-4","volume":"78","author":"HB Rubins","year":"1996","unstructured":"Rubins HB, Robins SJ, Collins D. The veterans affairs high-density lipoprotein intervention trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78:572\u20135.","journal-title":"Am J Cardiol"},{"key":"1117_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/clp.10.84","volume":"6","author":"M Elam","year":"2011","unstructured":"Elam M, Lovato L, Ginsberg H. The ACCORD-lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. J Clin Lipidol. 2011;6:9\u201320.","journal-title":"J Clin Lipidol"},{"key":"1117_CR47","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chr\u00e9tien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022\u201336.","journal-title":"Circ Res"},{"key":"1117_CR48","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJMp1508120","volume":"373","author":"BM Everett","year":"2015","unstructured":"Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors--the clinical benefit of lipid drugs. N Engl J Med. 2015;373:1588\u201391.","journal-title":"N Engl J Med"},{"key":"1117_CR49","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, de Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet (London, England). 2017;390:1962\u201371.","journal-title":"Lancet (London, England)"},{"key":"1117_CR50","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, et al. Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial. JAMA Cardiol. 2017;2:1385\u201391.","journal-title":"JAMA Cardiol"},{"key":"1117_CR51","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, de Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1117_CR52","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/dom.13114","volume":"19","author":"LA Leiter","year":"2017","unstructured":"Leiter LA, Cariou B, M\u00fcller-Wieland D, Colhoun HM, del Prato S, Tinahones FJ, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017;19:1781\u201392.","journal-title":"Diabetes Obes Metab"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-018-1117-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-018-1117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-018-1117-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T20:24:52Z","timestamp":1572294292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-018-1117-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1007\/s11892-018-1117-y","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"29 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ilaria Cavallari, Alessia Delli Veneri, Rosetta Melfi, Nicola Napoli, and Germano Di Sciascio declare that they have no conflict of interest.Ernesto Maddaloni has received speaker fees from Merck-Serono and grant support from scientific societies through AstraZeneca and Lilly.Giuseppe Patti is a speaker\/consultant\/advisory board member for Amgen, AstraZeneca, Bayer, BMS-Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Malesci, MSD, PIAM, Sanofi, and Sigma-Tau.Paolo Pozzilli received research funds and consulting fees from Sanofi, Lilly, and Medtronic, AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"138"}}